{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"64","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Progression is defined as a 25% increase in serum IgM from the lowest attained response value or progression of clinically significant disease related symptoms.","dispersionType":"Full Range","groups":[{"description":"RAD001, oral, 10 mg, daily\n\nRAD001: Taken orally once a day","id":"OG000","title":"RAD001"}],"paramType":"MEDIAN","populationDescription":"13 participants were excluded from this analysis due to treatment and follow-up ending prior to progression.","reportingStatus":"POSTED","timeFrame":"End of Treatment, an average of 16 months","title":"Time to Progression With Single Agent RAD001 Therapy in Previously Untreated WM.","type":"PRIMARY","unitOfMeasure":"Months"}